Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year)
›
›
Weismuellerstr. 50 60314 Frankfurt am Main Germany Dr Eckhard Guenther +49-069-42602-0 +49-069-42602-3444 info@aezsinc.com www.zentaris.com
›
ILF
› › › › › › ›
› ›
Areas of Activity
›
Biological Patents
›
External Collaborations
Request for Further Collaborations
Aeterna Zentaris GmbH
›
›
16 2001 Endocrinology, autoimmune and CNS diseases, vaccines, COVID-19, Chlamydia trachomatis, rare and orphan diseases, growth hormone deficiency Several patents and patent applications covering our products and projects filed or licensed in Big and medium-sized pharmaceutical companies together with academic institutions We are interested in in-licensing late stage preclinical or clinical opportunities in our areas of activity and are potentially seeking development partners for our projects.
In Pursuit of Medical Innovations Aeterna Zentaris (NASDAQ and TSX: AEZS) is a publicly listed, specialty biopharmaceutical company commercialising and developing therapeutics and diagnostic tests. Zentaris was founded in 2001 as a spin-off from ASTA Medica, the pharmaceutical division of Degussa AG, later acquired by Aeterna Laboratoires in Quebec, Canada, which led to the foundation of Aeterna Zentaris Inc. Aeterna Zentaris GmbH is the wholly owned German subsidiary located in Frankfurt am Main. The GmbH is the R&D and operations centre of the group, whereas the legal headquarters is in Toronto, Canada. In the past, Aeterna Zentaris successfully developed Cetrotide ® for in-vitro fertilisation, Impavido ® for the treatment of Leishmaniasis, and Lobaplatin for the treatment of solid tumours. All three products have been commercially available through global and local pharmaceutical companies for many years and have improved the lives of patients around the world. At present, our lead product macimorelin, a ghrelin receptor agonist, is the first and only approved oral drug indicated for diagnosis of adult growth hormone deficiency (AGHD) in the US and EU. Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Macimorelin has the potential to displace current testing procedures as a diagnostic standard. Our commercial and development partner for Macrilen™ for the US and Canada is Novo Nordisk, a global leader in endocrinology. In 2020 we entered into commercial agreements with Megapharm Ltd. to commercialise macimorelin in Israel and Palestine, and with Consilient Health Ltd., to commercialise macimorelin in Europe. Recently we entered into commercial agreements with Er-Kim Pharmaceuticals for Turkey and NK-Meditech Ltd. for Korea. Our business development efforts are ongoing to secure commercialisation partners for macimorelin in Asia and ROW.
